Drug intelligence / Profile preview

TetraFluvac TF

Development stage: Phase 2
Lead developer: Government Pharmaceutical Organization
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TetraFluvac TF is a seasonal tetravalent inactivated split virion influenza vaccine containing 15 μg of hemagglutinin (HA) per strain per dose. It is designed to protect against four different influenza virus strains.

Brand names: TetraFluvac TF

Targets

HA0 (Influenza B virus hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on TetraFluvac TF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TetraFluvac TF.

Explore the full profile